Expanded access to dapagliflozin for type 2 diabetes patients with high cardiovascular risk

Page last updated: 1 December 2024

On 1 December 2024, the Pharmaceutical Benefits Scheme (PBS) restrictions for dapagliflozin were expanded to allow treatment in combination with metformin (unless contraindicated/intolerant) with no glycaemic requirements for patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. This includes patients with cardiovascular disease, those at high risk of a cardiovascular event, and Aboriginal or Torres Strait Islander patients.

Further information is available on the PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines webpage.

If you have any questions relating to these changes, please email PBSpostmarket@health.gov.au